Celia Lin, MD

Assistant Clinical Professor

Education
- Internal Medicine Residency, Boston Medical Center
BS, - General Chemistry with Business and Administration Specialization, UCLA
- Rheumatology Fellowship, UCLA
MD, - , University of Rochester School of Medicine
- Rheumatology Fellowship and Post-doc, Washington University in St. Louis
Publications

  1. Lafayette R, Barbour S, Israni R, Wei X, Eren N, Floege J, Jha V, Kim SG, Maes B, Phoon RK, Singh H, Tesar V, Lin CJ, Barratt J. A Phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy. Kidney international 2024. PMID: 38552841


  2. Ghuman A, Khanna D, Lin CJF, Furst DE, Raghu G, Martinez FJ, Zucchetto M, Huang S, Jennings A, Nihtyanova SI, Denton CP. Prognostic and predictive markers of systemic sclerosis-associated interstitial lung disease in a clinical trial and long-term observational cohort. Rheumatology (Oxford, England) 2024. PMID: 37228011


  3. Sheng XR, Gao X, Schiffman C, Jiang J, Ramalingam TR, Lin CJF, Khanna D, Neighbors M. Biomarkers of fibrosis, inflammation, and extracellular matrix in the phase 3 trial of tocilizumab in systemic sclerosis. Clinical immunology (Orlando, Fla.) 2023. PMID: 37479123


  4. Isenberg DA, Lin CJF. Atacicept-it's not over until the wolf-lady sings (or maybe howls). Rheumatology (Oxford, England) 2023. PMID: 36087007


  5. Khanna D, Lin CJF, Furst DE, Wagner B, Zucchetto M, Raghu G, Martinez FJ, Goldin J, Siegel J, Denton CP. Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial. American journal of respiratory and critical care medicine 2022. PMID: 34851799


  6. Tom J, Bao M, Tsai L, Qamra A, Summers D, Carrasco-Triguero M, McBride J, Rosenberger CM, Lin CJF, Stubbings W, Blyth KG, Carratalà J, François B, Benfield T, Haslem D, Bonfanti P, van der Leest CH, Rohatgi N, Wiese L, Luyt CE, Kheradmand F, Rosas IO, Cai F. Prognostic and Predictive Biomarkers in Patients With Coronavirus Disease 2019 Treated With Tocilizumab in a Randomized Controlled Trial. Critical care medicine 2022. PMID: 34612846


  7. Kumar PN, Hernández-Sánchez J, Nagel S, Feng Y, Cai F, Rabin J, Morse CG, Nadig NR, Ashraf O, Gotur DB, McComsey GA, Gafoor K, Perin P, Thornton SC, Stubbings W, Lin CJF, Tsai L. Safety and Efficacy of Tocilizumab 4 or 8 mg/kg in Hospitalized Patients With Moderate to Severe Coronavirus Disease 2019 Pneumonia: A Randomized Clinical Trial. Open forum infectious diseases 2021. PMID: 35024375


  8. Roofeh D, Lin CJF, Goldin J, Kim GH, Furst DE, Denton CP, Huang S, Khanna D, focuSSced Investigators. Tocilizumab Prevents Progression of Early Systemic Sclerosis-Associated Interstitial Lung Disease. Arthritis & rheumatology (Hoboken, N.J.) 2021. PMID: 33538094


  9. Khanna D, Huang S, Lin CJF, Spino C. New composite endpoint in early diffuse cutaneous systemic sclerosis: revisiting the provisional American College of Rheumatology Composite Response Index in Systemic Sclerosis. Annals of the rheumatic diseases 2020. PMID: 33257497


  10. Khanna D, Lin CJF, Furst DE, Goldin J, Kim G, Kuwana M, Allanore Y, Matucci-Cerinic M, Distler O, Shima Y, van Laar JM, Spotswood H, Wagner B, Siegel J, Jahreis A, Denton CP, focuSSced investigators. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Respiratory medicine 2020. PMID: 32866440


  11. Gale SL, Trinh H, Mathew N, Jahreis A, Lin CJF, Sarsour K. Characterizing Disease Manifestations and Treatment Patterns Among Adults with Systemic Sclerosis: A Retrospective Analysis of a US Healthcare Claims Population. Rheumatology and therapy 2019. PMID: 31734871


  12. Bilezikian JP, Lin CJF, Brown JP, Wang AT, Yin X, Ebeling PR, Fahrleitner-Pammer A, Franek E, Gilchrist N, Miller PD, Simon JA, Valter I, Zerbini CAF, Libanati C, Chines A. Long-term denosumab treatment restores cortical bone loss and reduces fracture risk at the forearm and humerus: analyses from the FREEDOM Extension cross-over group. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2019. PMID: 31201481


  13. Ferrari S, Libanati C, Lin CJF, Brown JP, Cosman F, Czerwinski E, de Greg?rio LH, Malouf-Sierra J, Reginster JY, Wang A, Wagman RB, Lewiecki EM. Relationship Between Bone Mineral Density T-Score and Nonvertebral Fracture Risk Over 10 Years of Denosumab Treatment. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2019. PMID: 30919997


  14. Khanna D, Jahreis A, Lin CJF. Response to: 'Effectiveness and safety of tocilizumab for the treatment of refractory systemic sclerosis associated interstitial lung disease: a case series' by Narváez. Annals of the rheumatic diseases 2018. PMID: 30352886


  15. Lau AN, Wong-Pack M, Rodjanapiches R, Ioannidis G, Wade S, Spangler L, Balasubramanian A, Pannacciulli N, Lin CJF, Roy-Gayos P, Bensen WG, Bensen R, Adachi JD. Occurrence of Serious Infection in Patients with Rheumatoid Arthritis Treated with Biologics and Denosumab Observed in a Clinical Setting. The Journal of rheumatology 2017. PMID: 29142041


  16. Khanna D, Denton CP, Lin CJF, van Laar JM, Frech TM, Anderson ME, Baron M, Chung L, Fierlbeck G, Lakshminarayanan S, Allanore Y, Pope JE, Riemekasten G, Steen V, Müller-Ladner U, Spotswood H, Burke L, Siegel J, Jahreis A, Furst DE. Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate). Annals of the rheumatic diseases 2017. PMID: 29066464


  17. Adachi JD, Bone HG, Daizadeh NS, Dakin P, Papapoulos S, Hadji P, Recknor C, Bolognese MA, Wang A, Lin CJF, Wagman RB, Ferrari S. Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study. BMC musculoskeletal disorders 2017. PMID: 28449657


  18. Balasubramanian A, Wade SW, Adler RA, Lin CJF, Maricic M, O'Malley CD, Saag K, Curtis JR. Glucocorticoid exposure and fracture risk in patients with new-onset rheumatoid arthritis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2016. PMID: 27273113


  19. Papapoulos S, Lippuner K, Roux C, Lin CJ, Kendler DL, Lewiecki EM, Brandi ML, Czerwinski E, Franek E, Lakatos P, Mautalen C, Minisola S, Reginster JY, Jensen S, Daizadeh NS, Wang A, Gavin M, Libanati C, Wagman RB, Bone HG. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2015. PMID: 26202488


  20. Hammer GE, Turer EE, Taylor KE, Fang CJ, Advincula R, Oshima S, Barrera J, Huang EJ, Hou B, Malynn BA, Reizis B, DeFranco A, Criswell LA, Nakamura MC, Ma A. Expression of A20 by dendritic cells preserves immune homeostasis and prevents colitis and spondyloarthritis. Volume 12 of Issue 12. Nature immunology 2011. PMID: 22019834


  21. Li L, Fang CJ, Ryan JC, Niemi EC, Lebrón JA, Björkman PJ, Arase H, Torti FM, Torti SV, Nakamura MC, Seaman WE. Binding and uptake of H-ferritin are mediated by human transferrin receptor-1. Volume 107 of Issue 8. Proceedings of the National Academy of Sciences of the United States of America 2010. PMID: 20133674


  22. Liszewski MK, Leung MK, Hauhart R, Fang CJ, Bertram P, Atkinson JP. Smallpox inhibitor of complement enzymes (SPICE): dissecting functional sites and abrogating activity. Journal of immunology (Baltimore, Md. : 1950) 2009. PMID: 19667083


  23. Liszewski MK, Fang CJ, Atkinson JP. Inhibiting complement activation on cells at the step of C3 cleavage. Vaccine 2008. PMID: 19388160


  24. Fang CJ, Richards A, Liszewski MK, Kavanagh D, Atkinson JP. Advances in understanding of pathogenesis of aHUS and HELLP. British journal of haematology 2008. PMID: 18691170


  25. Fang CJ, Fremeaux-Bacchi V, Liszewski MK, Pianetti G, Noris M, Goodship TH, Atkinson JP. Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome. Blood 2007. PMID: 17914026


  26. Richards A, Kathryn Liszewski M, Kavanagh D, Fang CJ, Moulton E, Fremeaux-Bacchi V, Remuzzi G, Noris M, Goodship TH, Atkinson JP. Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome. Molecular immunology 2006. PMID: 16882452


  27. Caprioli J, Noris M, Brioschi S, Pianetti G, Castelletti F, Bettinaglio P, Mele C, Bresin E, Cassis L, Gamba S, Porrati F, Bucchioni S, Monteferrante G, Fang CJ, Liszewski MK, Kavanagh D, Atkinson JP, Remuzzi G, International Registry of Recurrent and Familial HUS/TTP. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 2006. PMID: 16621965


  28. La Cava A, Fang CJ, Singh RP, Ebling F, Hahn BH. Manipulation of immune regulation in systemic lupus erythematosus. Autoimmunity reviews 2005. PMID: 16214088


  29. Pearson TA, Bloch R, Dorantes J, Gordian A, Fang C, Swanson J, Brown K. The rationale for renewed interest by physicians in nutrition. Current atherosclerosis reports 1999. PMID: 11122707


  30. Staunton M, Dulitz MG, Fang C, Schmeling WT, Kampine JP, Farber NE. The effects of graded hypoxia on intraparenchymal arterioles in rat brain slices. Neuroreport 1998. PMID: 9631440


  31. Mchaourab HS, Oh KJ, Fang CJ, Hubbell WL. Conformation of T4 lysozyme in solution. Hinge-bending motion and the substrate-induced conformational transition studied by site-directed spin labeling. Biochemistry 1997. PMID: 9003182